When?
Start:
March 25, 2026
12:00 PM EST
End:
March 25, 2026
Speakers
Sabine Hutchison
CEO, Seuss
Bruno Gagnon
Senior Vice President, Clinical Dev Operations Spruce Biosciences
Andrei Atonescu
Head of Product, Clinical Maestro®
Anca Copaescu
Founder & CEO, Clinical Maestro®
Fundraising in biotech has changed.
It’s no longer enough to have strong science.
Investors now expect credible clinical plans, realistic budgets, and a clear execution strategy.
This session brings together real-world insights on how biotech teams can move from high-level assumptions to defensible, investor-ready clinical plans.
Why Many Biotech Fundraising Efforts Fall Short
Most challenges don’t come from the science.
They come from gaps in planning:
- timelines that don’t reflect execution reality
- budgets built on incomplete assumptions
- limited visibility into vendor costs and drivers
- disconnect between clinical, finance, and outsourcing
These gaps are quickly identified during investor discussions.
What Investors Actually Look For
Today’s investors are asking:
- How realistic are your timelines?
- How robust are your cost assumptions?
- How well do you understand execution complexity?
In short: Can this plan actually be delivered?
Where Clinical Plans Break Down
The biggest risks appear between: protocol design, budgeting, and execution.
Typical breakdowns include:
- underestimating global trial complexity
- misaligned assumptions across teams
- lack of structured RFP and vendor evaluation
- limited benchmarking of cost drivers
The result: delays, budget increases, and reduced confidence.
Outsourcing: Necessary — but Increasing Complexity
Outsourcing is not a shortcut.
It introduces:
- more vendors
- more dependencies
- more interfaces
Without structure:
- less visibility
- less control
- more risk
What Changes the Outcome
Biotech teams that succeed in fundraising:
- build budgets based on realistic scenarios
- understand key cost drivers and assumptions
- align clinical, financial, and outsourcing perspectives
- bring structure into RFP and vendor evaluation
They move from estimates to defensible plans.
Key Takeaways
- fundraising success depends on operational credibility
- clinical planning must reflect execution reality
- outsourcing strategy impacts budgets and timelines
- structured data and benchmarking improve confidence
Apply This to Your Programs
If you are preparing for fundraising or planning your next study:
👉 Request a Demo to explore how to bring more structure and confidence into your clinical planning.
Strengthen your processes and increase data-driven decision-making for faster study start-ups.
When?
Start:
March 25, 2026
12:00 PM EST
End:
March 25, 2026
Speakers
Sabine Hutchison
CEO, Seuss
Bruno Gagnon
Senior Vice President, Clinical Dev Operations Spruce Biosciences
Andrei Atonescu
Head of Product, Clinical Maestro®
Anca Copaescu
Founder & CEO, Clinical Maestro®
Strengthen your processes and increase data-driven decision-making for faster study start-ups.
RESOURCES
Explore Expert Insights and Resources for Clinical Excellence
Webinars
Oversight is no longer periodic or document-driven. It must be continuous, risk-based, and fully traceable across vendors, studies, and services.
Blogs
From Vendor Management to Real-Time Control in Clinical Trials
Case Studies
Faced with inefficiencies, compliance risks, and fragmented communication, a biopharma company dramatically enhanced its vendor governance by implementing VISION!
DEMO
Request a demo
Discover how Clinical Maestro®’s advanced solutions can streamline your clinical trial operations. Request a personalized demo to explore how our tools transform budgeting, vendor management, and outsourcing efficiency for pharma and biotech.

